Our findings demonstrate the effectiveness of vertical inhibition of the PI3K pathway in PIK3CA-mutant CRC, providing a promising approach for more effective and safer therapeutic intervention in mCRC, a field bereft of meaningful impact on 5-year survival rates. This evidence concerns the gene PIK3CA and colorectal carcinoma.